A Randomized, Double-Blind, Midazolam-Controlled Trial of Low-Dose Ketamine Infusion in Patients With Treatment-Resistant Depression and Prominent Suicidal Ideation
International Journal of Neuropsychopharmacology · 31.05.2023 · 26 (5) · 331-339
DOI: 10.1093/ijnp/pyad014 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Neuropsychopharmacology, online erschienen am 26.03.2023. Verfasst von Tung-Ping Su und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Taipei Veterans General Hospital, Taipei, Taiwan. Hauptthemen laut MEDLINE: Ketamine, Major Depressive Disorder, Depressive Disorder, Treatment-Resistant. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Taipei Veterans General Hospital, Yen Tjing Ling Medical Foundation, Ministry of Science and Technology, Taiwan.
Themen: Depression
Abstract (Originalsprache)
Background
The benefits of low-dose ketamine for patients with treatment-resistant depression (TRD) and prominent suicidal ideation require further investigation. The effects of treatment refractoriness, the duration of the current depressive episode, and the number of prior antidepressant failures on ketamine efficacy also require clarification.
Methods
We recruited 84 outpatients with TRD and prominent suicidal ideation—defined as a score ≥4 on item 10 of the Montgomery–Åsberg Depression Rating Scale (MADRS)—and randomized them into 2 groups to receive 0.5 mg/kg ketamine or 0.045 mg/kg midazolam. We assessed depressive and suicidal symptoms prior to infusion; 240 minutes post infusion; and 2, 3, 5, 7, and 14 days post infusion.
Results
According to the MADRS scores, the antidepressant effect (P = .035) was significantly noted in the ketamine group up to 14 days than in the midazolam group. However, the antisuicidal effect of ketamine, as measured by the Columbia-Suicide Severity Rating Scale Ideation Severity Subscale (P = .040) and MADRS item 10 (P = .023), persisted only 5 days post infusion. Furthermore, the antidepressant and antisuicidal effects of ketamine infusion were noted particularly in patients whose current depressive episode lasted <24 months or whose number of failed antidepressants was ≤4.
Conclusions
Low-dose ketamine infusion is a safe, tolerable, and effective treatment for patients with TRD and prominent suicidal ideation. Our study highlights the importance of timing; specifically, ketamine is more likely to achieve therapeutic response when the current depressive episode lasted <24 months and the number of failed antidepressants is ≤4.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, Taipei Veterans General Hospital, Taipei, Taiwan.
- Division of Psychiatry, Faculty of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
- Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan.
- Institute of Brain Science, National Yang Ming Chiao Tung University, Taipei, Taiwan.
- Department of Psychiatry, Cheng Hsin General Hospital, Taipei, Taiwan.
- Institute of Biomedical Informatics, National Yang Ming Chiao Tung University, Taipei, Taiwan.
ORCID-Profile: Cheng-Ta Li, Shih-Jen Tsai, Mu-Hong Chen
Förderung
- Taipei Veterans General Hospital
- Yen Tjing Ling Medical Foundation
- Ministry of Science and Technology, Taiwan
- Taipei, Taichung, Kaohsiung Veterans General Hospital
- Tri-Service General Hospital
- Academia Sinica Joint Research Program
- Veterans General Hospitals
- University System of Taiwan Joint Research Program
Zitieren
APA
Su, T. P., Li, C. T., Lin, W. C., Wu, H. J., Tsai, S. J., Bai, Y. M., Mao, W. C., Tu, P. C., Chen, L. F., Li, W. C., & Chen, M. H. (2023). A Randomized, Double-Blind, Midazolam-Controlled Trial of Low-Dose Ketamine Infusion in Patients With Treatment-Resistant Depression and Prominent Suicidal Ideation. International Journal of Neuropsychopharmacology, 26(5), 331-339. https://doi.org/10.1093/ijnp/pyad014
Vancouver
Su TP, Li CT, Lin WC, Wu HJ, Tsai SJ, Bai YM, et al. A Randomized, Double-Blind, Midazolam-Controlled Trial of Low-Dose Ketamine Infusion in Patients With Treatment-Resistant Depression and Prominent Suicidal Ideation. International Journal of Neuropsychopharmacology. 2023;26(5):331-339. doi:10.1093/ijnp/pyad014
BibTeX
@article{Su2023,
author = {Su, Tung-Ping and Li, Cheng-Ta and Lin, Wei-Chen and Wu, Hui-Ju and Tsai, Shih-Jen and Bai, Ya-Mei and Mao, Wei-Chung and Tu, Pei-Chi and Chen, Li-Fen and Li, Wei-Chi and Chen, Mu-Hong},
title = {A Randomized, Double-Blind, Midazolam-Controlled Trial of Low-Dose Ketamine Infusion in Patients With Treatment-Resistant Depression and Prominent Suicidal Ideation},
journal = {International Journal of Neuropsychopharmacology},
year = {2023},
volume = {26},
number = {5},
pages = {331--339},
doi = {10.1093/ijnp/pyad014}
}
EUVIMED